WP
ASBP

Woodline Partners’s Aspire Biopharma ASBP Stock Holding History

Woodline Partners’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-167
Closed -$2.1M – 771
2023
Q1 		$2.1M Hold
167
– – 0.03% 413
2022
Q4 		$2.06M Hold
167
– – 0.03% 468
2022
Q3 		$2.03M Hold
167
– – 0.03% 453
2022
Q2 		$2M Buy
+167
New +$2M 0.03% 423

Other funds holding ASBP

PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
AI
Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
ETH
Exos TFP Holdings New York $162M AUM 16.08% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

Woodline Partners's ASBP Position: Q2 2023 in Review

Woodline Partners sold out of Aspire Biopharma (ASBP) in Q2 2023, closing a stake of 167 shares — an estimated $2.1M sold.

Woodline Partners first reported a position in ASBP in Q2 2022 and held it in 4 quarters. The position peaked at $2.1M in Q1 2023. 14 funds tracked by Wall St. Rank hold ASBP as of Q2 2023.

  • Woodline Partners reported no remaining Aspire Biopharma position as of Q2 2023 after selling out during the quarter.
  • Woodline Partners sold 167 Aspire Biopharma shares in Q2 2023, an estimated $2.1M.
  • Woodline Partners first reported a position in Aspire Biopharma in Q2 2022 and held it in 4 quarters.
  • Woodline Partners's Aspire Biopharma position peaked at $2.1M in Q1 2023.
  • 14 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2023.

Based on Woodline Partners's 13F filing for Q2 2023, filed 14 Aug 2023.